Background. Early recognition of deep seated infections (osteomyelitis and abscesses) in the pediatric population may be difficult, given nonspecific symptoms and signs but remains crucial in the management. There is increasing emphasis on ionizing radiation dose reduction, making whole-body MRI (WBMRI) with short TI inversion recovery (STIR) the advanced imaging modality of choice over bone scintigraphy and CT-scans.
Methods. A retrospective chart review of pediatric patients, <19 years, at Palmetto Health, Columbia, SC who had WBMRI with infectious indications during 9/2011 to 12/2013 was performed. The aims of this research were to describe complications related to sedation/contrast, to determine what portion of patients had new evidence of deep seated infections and to obtain initial evidence for effectiveness of WBMRI.
Results. 20 patients were included with male predominance (12; 60%). 9/20 patients < 12 months old and 4 between the ages of 12-70 months. The most common comorbidity was sickle cell syndrome (n = 6) and 16/20 patients had a recent/current central venous catheter. The reasons for imaging were fever (9, 45%), pain/swelling (5, 25%), and abnormal labs/imaging (6, 30%). 19 patients had other diagnostics studies prior to WBMRI, 17 of whom had ionizing radiation using studies (X-rays / CT scans). 10/19 also had additional trips to the radiology department for focal MRIs. Duration of sedation for WBMRI averaged 88 minutes, with propofol (10/14) being the most common agent used. No complications from the sedation or the MRI contrast were recorded. WBMRI found an average of 1-4 areas of osteomyelitis in 11 patients and up to 8 other locations of deep seated infections in 15 patients. 11/20 had post WBMRI surgical intervention of debridement/drainage. Gram-positive cocci were isolated from 10/17 patients with positive blood/tissue cultures. Of those, 6 were methicillin-resistant Staphylococcus aureus.
Conclusion. Utilized as an early imaging modality in pediatric patients with persistent bacteremia/fevers, WBMRI commonly facilitated timely definitive interventions while sparing the patient exposure to ionizing radiation. WBMRI with STIR was safe and is likely to be cost effective.
Disclosures. Methods. We examined findings from two longitudinal studies of children 5 to 15 years of age who had throat cultures performed for the detection of GAS while endorsing at least one symptom consistent with streptococcal pharyngitis. Cohort 1 was a surveillance study in which cultures were performed at regular intervals and with illnesses. Cohort 2 were children who were selectively tested by their care providers and then followed. Symptoms were assessed systematically at the time of the first positive culture. Each participant had at least two follow-up cultures performed between 7-21 days and 22-35 days after the first culture. We defined acute infection as two or more negative follow-up cultures for GAS and carriage as two or more positive follow-up cultures in the absence of symptoms. We compared symptoms at the time of the first positive culture between those with acute infection or carriage using chisquare statistics.
Results. A total of 181 children contributed 228 symptomatic episodes; 52% were female, with a mean age of 8.9 years. In cohort 1: 96/122 (79%) were acute infections vs. 26/122 (21%) were carriers. Children endorsed at least one upper respiratory symptom (other than sore throat) in 40/65 (62%) of those with acute infection and 13/21 (62%) in those who were carriers (P = 0.976). In cohort 2: 94/106 (89%) were acutely infected and 12/106 (11%) were carriers. Children had at least one upper respiratory symptom in 24/94 (26%) acute infection and 6/12 (50%) of carriers (P = 0.076). In cohort 2, symptoms of nasal congestion alone (P = 0.009), vomiting (P = 0.018), and abdominal pain (P = 0.015) were more common among carriers compared with acutely infected. There was no difference in severity score or duration of symptoms.
Conclusion. This study highlights that when children are selectively tested for GAS based on clinical judgement fewer GAS carriers are identified. For those who were selectively tested, clinical symptoms, including nasal congestion, were more common in children identified as GAS carriers.
Disclosures. All authors: No reported disclosures. to children with asthma, we tested the hypothesis that mammalian pets could harbor respiratory pathogens of relevance to disease exacerbation among inner-city children with asthma.
Household Pets and Recovery of
Methods. We tested nasal and pharyngeal biospecimens from subset of 5-17 years old primarily African-American children with asthma enrolled in an ongoing cohort (ECATCh, NCT02251379) prior to trial randomization. At a home visit within three weeks prior to the clinic visit at which children were swabbed, mammalian pets whose owners consented to participate were sampled at nares, mouth, and perineum, depending on animal access and temperament. Aliquots (400 µL) of medium from Copan e-swabs from children and mammalian pets were cultured for multiple respiratory pathogens at the clinical microbiology laboratory at Johns Hopkins Hospital.
Results. We evaluated 95 children with asthma and 60 mammalian pets at the baseline clinic and home visits, respectively. In children, carriage of respiratory pathogens was: Staphylococcus aureus, 36.8%; Moraxella catarrhalis, 8.4%; Group A Strep, 7.4%; Streptococcus pneumoniae, 1%. In mammalian pets, carriage of respiratory pathogens was: Moraxella catarrhalis, 11.7% (1 dog, 6 cats where 5 of the cats were in the same household); Streptococcus pneumoniae, 1.7% (1 dog). In the home where the dog carried Moraxella catarrhalis (perineum site), the child also carried Moraxella catarrhalis (nares site). Children with dogs had 8-fold higher odds of detection of Moraxella catarrhalis (95% Confidence Interval: 1.4, 46.9, P = 0.02), controlling for other pet ownership and demographic variables. Dogs had higher contact with child participants than cats (contact score higher by 0.7 points on average, P < 0.05).
Conclusion. Mammalian pets may harbor respiratory pathogens, including Moraxella catarrhalis. Future studies are needed to determine the direction of transmission and whether mammalian pets can serve as a vehicle or reservoir of pathogens of relevance to respiratory disease in children.
Disclosures. All authors: No reported disclosures. 
Higher Pediatric Vancomycin Dosing Trends Toward Improved Therapeutic Troughs

Background.
Vancomycin is challenging to dose due to a narrow therapeutic index. Inadequate dosing undertreats dangerous infections, while high doses can cause Acute Kidney Injury (AKI). Standard pediatric vancomycin dosing (40-60 mg/kg/day) often produces inadequate troughs. Our institution began permitting a higher initial vancomycin dose: 80 mg/kg/day for children 1 month to 12 years old, and 60 mg/kg/day for children ≥ 13 years old. This study aims to determine whether higher dosing has increased the rate of therapeutic troughs or the rate of AKI.
Methods. A retrospective review was conducted of patients < 18 years of age who were admitted to our institution and received vancomycin. 842 unique courses of vancomycin were identified and age, sex, race, vancomycin dosing, trough results, and creatinine data were abstracted. 450 records were excluded based on criteria of age < 1 month, pre-existing renal failure, or no measured troughs. 392 unique vancomycin courses for 340 unique patients were analyzed. Therapeutic troughs were defined as 10-20 µg/mL. Statistical analysis was performed using Chi-square test, Fisher's exact test, and unpaired t-test.
Results. Younger patients with higher vancomycin dosing attained an initial therapeutic trough in 41.1% vs. 32.7%.
Conclusion. A higher initial vancomycin dose trended toward an improved rate of therapeutic troughs in children 1 month to 12 years old. There was no evidence of increase in the rate of AKI or supratherapeutic troughs. While vancomycin dosing remains challenging, a policy permitting higher initial dosing may more adequately treat dangerous infections without risking adverse effects. Further study of higher vancomycin dosing is warranted.
Disclosures. All authors: No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. Aerosolized or powdered forms of polymyxin have been used as prophylaxis for ventilator associated infections in adults. In 2015, Children's National Medical Center neonatal intensive care unit (NICU) protocol recommended that neonates <1,000 g receive polymyxin endotracheal tube suction catheter flushes with the goal to reduce acquired respiratory infection. The objective of this study was to describe the clinical characteristics and outcomes of patients who received polymyxin endotracheal tube flushes compared with those who received saline.
Practice of Endotracheal Tube Suction Catheter Flushes With Polymyxin in Extremely Low Birthweight Neonates
Methods. A retrospective cohort study of infants weighing <1,000 g ventilated for >48 hours in the NICU, January 1, 2015-June 30, 2016 was performed. Data were collected from an internal NICU database, medication billing data, and through chart review of the electronic health record. Demographics, antibiotic treatment days, ventilator days, length of stay, mortality, and microbiologic culture data were compared between patients receiving polymyxin and saline using chi-squared for binary and t-test for continuous variables.
Results. Of the 71 patients included, 38 received polymyxin and 33 received saline. Mean gestational age at birth was 24.1 weeks (23.9 polymyxin vs. 24.2 saline, P = 0.06); median age on admission 4 days (3 vs 12, P = 0.019); median admission weight 700 g (640 vs. 800, P = 0.002); 52% were male (58% vs. 45% group). Median antibiotic days was 52 (77 vs. 41, P = 0.056), median ventilator days 39 (43.5 vs. 33, P = 0.06). Pathogenic bacteria was cultured in 38% of patients in whom at least one lower respiratory tract (LRT) culture was obtained (62.5% vs. 38.1% P = 0.24). Pathogenic bacteria resistant to at least one antibiotic class to which is normally susceptible was found in 10% (13% vs. 6%, P = 0.32). No differences were seen in mortality (16% vs. 15%, P = 0.94) or median length of stay (101 vs. 92, P = 0.41).
Conclusion. An NICU protocol recommending prophylactic polymyxin use for ELBW infants was implemented more frequently in younger and more premature neonates. Mortality and length of stay did not differ among babies who received polymyxin. Patients who received polymyxin did not grow a statistically significant higher proportion of pathogenic or resistant bacteria from LRT cultures compared with those receiving saline.
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